Nephros (NEPH) Q4 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Source: NASDAQ.COM
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NEPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NEPH
Wall Street analysts forecast NEPH stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.660
Low
8.00
Averages
8.00
High
8.00
Current: 3.660
Low
8.00
Averages
8.00
High
8.00
About NEPH
Nephros, Inc. is a water technology company providing filtration solutions to the medical and commercial markets. The Company provides water filtration products and services, along with water-quality education. In the medical markets, it sells water filtration products. In the commercial market, it manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, heavy metals, chemical compounds, scale build-up in downstream equipment, and various other contaminants. Its products are marketed primarily to the food service, hospitality, convenience store, and healthcare markets. These commercial products are also marketed in medical markets as supplemental filtration to its medical filters. Its filters are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nephros Achieves Record Revenue in Q1 2026
- Revenue Growth: Nephros achieved $5.2 million in revenue for Q1 2026, marking the first time it surpassed the $5 million threshold, reflecting a year-over-year increase of approximately 7%, indicating strong performance in key markets despite ongoing margin pressures and cost challenges.
- Gross Margin Decline: The gross margin for the first quarter was 57%, down from 65% in the prior year, primarily due to tariffs and product mix changes that resulted in over $200,000 in additional costs, highlighting the challenges faced as the company expands into commercial applications.
- Cash Flow Status: As of March 31, 2026, Nephros had approximately $4 million in cash and remained debt-free, although the cash balance declined due to the timing of inventory receipts and accounts receivable collections, demonstrating prudent financial management amid operational fluctuations.
- Market Outlook: Management expressed optimism about future growth, emphasizing expansion in key markets such as New York and Puerto Rico, along with continued contributions from programmatic installations and replacements, although short-term margin variability may arise from tariffs and product mix fluctuations.
See More
Nephros Q1 Earnings Beat Expectations
- Earnings Performance: Nephros reported Q1 GAAP EPS of $0.01, aligning with market expectations, while revenue reached $5.21 million, reflecting a 6.8% year-over-year increase and beating estimates by $0.22 million, indicating stability in revenue growth.
- Market Reaction: Despite the earnings beat, Nephros shares fell 6.8% in after-hours trading, reflecting investor concerns about future growth prospects, which may impact short-term market confidence in the company.
- Historical Performance Comparison: Compared to historical data, Nephros's revenue growth rate shows some improvement, suggesting a gradual strengthening in market competitiveness, yet ongoing scrutiny of its sustained profitability is necessary.
- Future Outlook: Investors should closely monitor Nephros's upcoming earnings reports and market strategies to assess its long-term growth potential in the medical device industry and its ability to navigate market fluctuations.
See More
Nephros Reports Significant Growth in 2025 Financials
- Significant Revenue Growth: Nephros reported total revenue of $18.8 million for 2025, a 33% increase from $14.2 million in 2024, indicating strong market performance and growth potential.
- Sustained Profitability: The company achieved a net income of $1.2 million in 2025, a substantial rise from $0.1 million in 2024, marking its second consecutive year of profitability and boosting investor confidence.
- Expanded Customer Base: By the end of 2025, active customer sites exceeded 1,680, up from over 1,500 in 2024, demonstrating success in market penetration and customer acquisition.
- Increased R&D Investment: R&D expenses reached $1.3 million in 2025, up 57% from $0.9 million in 2024, reflecting the company's commitment to innovation and product development, although this has impacted short-term profitability.
See More
Nephros (NEPH) Q4 2025 Earnings Call Transcript
See More
Nephros Q4 Earnings Beat Expectations
- Earnings Highlights: Nephros reported a Q4 GAAP EPS of $0.01, meeting market expectations, while revenue reached $4.7 million, reflecting a 20.5% year-over-year increase and beating estimates by $0.25 million, indicating robust performance in the market.
- Growth Drivers: The significant revenue growth is primarily attributed to ongoing innovations in the medical device sector and increased market demand, further solidifying the company's competitive position within the industry.
- Market Reaction: Following the earnings release, investors expressed optimism regarding Nephros's future growth prospects, anticipating continued benefits from the expansion of the healthcare sector and technological advancements.
- Future Outlook: Nephros's sustained growth and improved profitability may attract more investor interest, potentially enhancing the company's performance in future capital markets.
See More
Nephros Enters Puerto Rican Market with Filtration Solutions
- Market Opportunity: Nephros estimates a $10 million opportunity in Puerto Rico across healthcare, foodservice, and hospitality sectors, with healthcare and foodservice each representing $3 million, highlighting urgent needs for water safety.
- Localized Service: The company plans to differentiate itself by offering rapid response from a dedicated inventory network, on-site installation, and Spanish-language customer support, thereby enhancing its competitive edge in the market.
- Technological Advantage: Nephros' filtration solutions focus on microbial control and compliance with drinking water contaminants, aiming to fill the long-standing gap in high-quality filtration in Puerto Rico, thereby enhancing public health safety.
- Strategic Expansion: This market entry is a natural extension of Nephros' core strategy, aiming to leverage advanced technology to meet critical water safety needs while expanding into sectors beyond traditional patient care, driving overall company growth.
See More
Nephros Achieves Record Revenue in Q1 2026
- Revenue Growth: Nephros achieved $5.2 million in revenue for Q1 2026, marking the first time it surpassed the $5 million threshold, reflecting a year-over-year increase of approximately 7%, indicating strong performance in key markets despite ongoing margin pressures and cost challenges.
- Gross Margin Decline: The gross margin for the first quarter was 57%, down from 65% in the prior year, primarily due to tariffs and product mix changes that resulted in over $200,000 in additional costs, highlighting the challenges faced as the company expands into commercial applications.
- Cash Flow Status: As of March 31, 2026, Nephros had approximately $4 million in cash and remained debt-free, although the cash balance declined due to the timing of inventory receipts and accounts receivable collections, demonstrating prudent financial management amid operational fluctuations.
- Market Outlook: Management expressed optimism about future growth, emphasizing expansion in key markets such as New York and Puerto Rico, along with continued contributions from programmatic installations and replacements, although short-term margin variability may arise from tariffs and product mix fluctuations.
See More
Nephros Q1 Earnings Beat Expectations
- Earnings Performance: Nephros reported Q1 GAAP EPS of $0.01, aligning with market expectations, while revenue reached $5.21 million, reflecting a 6.8% year-over-year increase and beating estimates by $0.22 million, indicating stability in revenue growth.
- Market Reaction: Despite the earnings beat, Nephros shares fell 6.8% in after-hours trading, reflecting investor concerns about future growth prospects, which may impact short-term market confidence in the company.
- Historical Performance Comparison: Compared to historical data, Nephros's revenue growth rate shows some improvement, suggesting a gradual strengthening in market competitiveness, yet ongoing scrutiny of its sustained profitability is necessary.
- Future Outlook: Investors should closely monitor Nephros's upcoming earnings reports and market strategies to assess its long-term growth potential in the medical device industry and its ability to navigate market fluctuations.
See More
Nephros Reports Significant Growth in 2025 Financials
- Significant Revenue Growth: Nephros reported total revenue of $18.8 million for 2025, a 33% increase from $14.2 million in 2024, indicating strong market performance and growth potential.
- Sustained Profitability: The company achieved a net income of $1.2 million in 2025, a substantial rise from $0.1 million in 2024, marking its second consecutive year of profitability and boosting investor confidence.
- Expanded Customer Base: By the end of 2025, active customer sites exceeded 1,680, up from over 1,500 in 2024, demonstrating success in market penetration and customer acquisition.
- Increased R&D Investment: R&D expenses reached $1.3 million in 2025, up 57% from $0.9 million in 2024, reflecting the company's commitment to innovation and product development, although this has impacted short-term profitability.
See More
Nephros (NEPH) Q4 2025 Earnings Call Transcript
See More
Nephros Q4 Earnings Beat Expectations
- Earnings Highlights: Nephros reported a Q4 GAAP EPS of $0.01, meeting market expectations, while revenue reached $4.7 million, reflecting a 20.5% year-over-year increase and beating estimates by $0.25 million, indicating robust performance in the market.
- Growth Drivers: The significant revenue growth is primarily attributed to ongoing innovations in the medical device sector and increased market demand, further solidifying the company's competitive position within the industry.
- Market Reaction: Following the earnings release, investors expressed optimism regarding Nephros's future growth prospects, anticipating continued benefits from the expansion of the healthcare sector and technological advancements.
- Future Outlook: Nephros's sustained growth and improved profitability may attract more investor interest, potentially enhancing the company's performance in future capital markets.
See More
Nephros Enters Puerto Rican Market with Filtration Solutions
- Market Opportunity: Nephros estimates a $10 million opportunity in Puerto Rico across healthcare, foodservice, and hospitality sectors, with healthcare and foodservice each representing $3 million, highlighting urgent needs for water safety.
- Localized Service: The company plans to differentiate itself by offering rapid response from a dedicated inventory network, on-site installation, and Spanish-language customer support, thereby enhancing its competitive edge in the market.
- Technological Advantage: Nephros' filtration solutions focus on microbial control and compliance with drinking water contaminants, aiming to fill the long-standing gap in high-quality filtration in Puerto Rico, thereby enhancing public health safety.
- Strategic Expansion: This market entry is a natural extension of Nephros' core strategy, aiming to leverage advanced technology to meet critical water safety needs while expanding into sectors beyond traditional patient care, driving overall company growth.
See More
